Found: 4
Select item for more details and to access through your institution.
Safety of Lutetium-177 prostate-specific membrane antigen-617 (PSMA-617) radioligand therapy in the setting of severe renal impairment: a case report and literature review.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231177018
- By:
- Publication type:
- Article
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [<sup>161</sup>Tb]Tb-PSMA-I&T.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.124.267650
- By:
- Publication type:
- Article
Telehealth‐based pre‐operative education session for robot‐assisted radical prostatectomy patients—A 2‐year follow‐up study.
- Published in:
- International Journal of Urological Nursing, 2024, v. 18, n. 2, p. 1, doi. 10.1111/ijun.12398
- By:
- Publication type:
- Article
Patient‐centred pathology reporting improves patient experience and understanding of disease in prostate cancer care.
- Published in:
- BJUI Compass, 2024, v. 5, n. 4, p. 497, doi. 10.1002/bco2.322
- By:
- Publication type:
- Article